ClinicalTrials.gg

Program

Injectable ALK-N001

A development code. Also written as “ALK-N001 for Injection”.

Its studies are led by Zhejiang Anglikang Pharmaceutical.

Furthest: phase 2, since Mar 23, 20263 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zhejiang Anglikang Pharmaceutical32 open or runningphase 2since Mar 23, 2026Mar 23, 2026Dec 2027phase 2 · NCT07826195

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 23, 2026First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07509684 · 190 planned
  2. Apr 8, 2026Phase 1 study in Advance Solid TumorsNCT07529535 · 16 enrolled · China
  3. Sep 13, 2026Phase 2 study in Advanced Gastrointestinal TumorsNCT07826195 · 174 planned

Ahead

  1. Dec 2027Primary completion: phase 2 study in Advanced Gastrointestinal TumorsNCT07826195
  2. Dec 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT07509684

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07826195Advanced Gastrointestinal Tumors2Not yet recruitingDec 2027174
NCT07529535Advance Solid Tumors · China1SuspendedDec 202616
NCT07509684Advanced Solid Tumors2Not yet recruitingDec 2027190

How it is read

Names in the registry

  • “ALK-N001 for Injection”, 2 entries
  • “Injectable ALK-N001”, 1 entry

Codes read as this program: QHL1618.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.